Drugs / NM-IL-12
NM-IL-12
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01742221 | Aug → Nov 2012 | acute radiation syndrome | Neumedicines Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00005655 | Apr 2000 → Oct 2010 | breast neoplasm, kidney neoplasm, lung neoplasm, sarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00001906 | Apr 1999 → May 2001 | cutaneous leishmaniasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02544724 | Nov 2016 → Aug 2017 | diffuse large B-cell lymphoma | Neumedicines Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT02544061 | Mar 2016 → Oct 2017 | diversion colitis | Neumedicines Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02542124 | Dec 2015 → Feb 2019 | Sezary syndrome, mycosis fungoides | Neumedicines Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT02343133 | Jan 2015 → Apr 2016 | acute radiation syndrome | Neumedicines Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00203879 Background | Feb 2002 → May 2006 | metastatic melanoma | University of Chicago | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NM-IL-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02542124 ↗ |
| Known as | HemaMax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02343133 ↗ |
| Known as | recombinant human interleukin-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001906 ↗ |
| Known as | rhIL-12 | “Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants” NCT00001906 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human IL-12 administered intravenously” NCT00005655 ↗ |
| Route | Intravenous | “rhIL-12 will be administered intravenously” NCT00005655 ↗ |